We are live on ! Find out more
VAIA

Virtus Alternative Investment Advisers Portfolio holdings

AUM $6.71M
1-Year Est. Return 36.98%
This Fund
S&P 500
This Quarter Est. Return
+15.08%
1 Year Est. Return
+36.98%
3 Year Est. Return
+42.83%
5 Year Est. Return
10 Year Est. Return
AUM
$6.71M
AUM Growth
+$1.27M
Cap. Flow
+$345K
Cap. Flow %
5.15%
Top 10 Hldgs %
47.64%
Holding
286
New
20
Increased
6
Reduced
248
Closed
6

Top Sells

Rank Stock Value
1
WSO icon
Watsco Inc
WSO
+$101K
2
MU icon
Micron Technology
MU
+$87K
3
MRK icon
Merck
MRK
+$66K
4
QCOM icon
Qualcomm
QCOM
+$50.6K
5
AVGO icon
Broadcom
AVGO
+$48K

Sector Composition

Rank Sector Weight
1 Industrials 16.11%
2 Technology 14.44%
3 Communication Services 14.32%
4 Healthcare 10.11%
5 Financials 6.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UNF icon
151
Unifirst Corp
UNF
$5.32B
$7K 0.1%
31
-29
-48% -$5.52K
VICR icon
152
Vicor
VICR
$9.98B
$7K 0.1%
72
-70
-49% -$5.88K
WAT icon
153
Waters Corp
WAT
$36.9B
$7K 0.1%
29
-90
-76% -$20.4K
WINA icon
154
Winmark
WINA
$1.21B
$7K 0.1%
36
-35
-49% -$6.22K
YMAB
155
DELISTED
Y-mAbs Therapeutics
YMAB
$7K 0.1%
147
-654
-82% -$30.3K
BCPC
156
Balchem Corp
BCPC
$5.21B
$7K 0.1%
59
-57
-49% -$6.01K
NVRO
157
DELISTED
NEVRO CORP.
NVRO
$7K 0.1%
39
-38
-49% -$6.15K
EGRX
158
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$7K 0.1%
141
-137
-49% -$6.41K
WIRE
159
DELISTED
Encore Wire Corp
WIRE
$7K 0.1%
123
-118
-49% -$6.1K
KRTX
160
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$7K 0.1%
71
-68
-49% -$6.3K
MRTX
161
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7K 0.1%
34
-33
-49% -$7.13K
NATI
162
DELISTED
National Instruments Corp
NATI
$7K 0.1%
161
-156
-49% -$5.82K
CSII
163
DELISTED
Cardiovascular Systems, Inc.
CSII
$7K 0.1%
160
-154
-49% -$5.79K
ABMD
164
DELISTED
Abiomed Inc
ABMD
$7K 0.1%
21
-20
-49% -$5.53K
CCXI
165
DELISTED
ChemoCentryx, Inc.
CCXI
$7K 0.1%
106
-103
-49% -$5.9K
AVLR
166
DELISTED
Avalara, Inc.
AVLR
$7K 0.1%
45
-44
-49% -$7.04K
DSPG
167
DELISTED
DSP Group Inc
DSPG
$7K 0.1%
434
-420
-49% -$6.46K
XLRN
168
DELISTED
Acceleron Pharma
XLRN
$7K 0.1%
51
-50
-50% -$5.86K
EGOV
169
DELISTED
NIC Inc
EGOV
$7K 0.1%
277
-268
-49% -$6.23K
AOS icon
170
A.O. Smith
AOS
$8.39B
$6K 0.09%
107
-103
-49% -$5.68K
ATEX icon
171
Anterix
ATEX
$1.9B
$6K 0.09%
155
-149
-49% -$4.91K
BAH icon
172
Booz Allen Hamilton
BAH
$8.9B
$6K 0.09%
64
-63
-50% -$5.36K
BF.B icon
173
Brown-Forman Class B
BF.B
$12B
$6K 0.09%
74
-71
-49% -$5.48K
BF.A icon
174
Brown-Forman Class A
BF.A
$12.3B
$6K 0.09%
82
-79
-49% -$5.67K
BIO icon
175
Bio-Rad Laboratories Class A
BIO
$8.45B
$6K 0.09%
11
-10
-48% -$5.7K

Similar funds

Virtus Alternative Investment Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus Alternative Investment Advisers held 286 positions worth $6.71M, up 23% from $5.44M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Virtus Alternative Investment Advisers deployed $345K of net new capital in Q4 2020, opening 20 new positions and adding to 6 existing holdings. Its largest new stake was Invesco DB Gold Fund: 29,703 shares worth $1.64M.

By sector, the portfolio is most concentrated in Industrials at 16% of assets, down from 21% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Watsco Inc, an estimated $101K trimmed.

  • Virtus Alternative Investment Advisers's largest Q4 2020 buy was Invesco DB Gold Fund: 29,703 shares worth $1.64M.
  • Virtus Alternative Investment Advisers added most to Charter Communications in Q4 2020, an estimated $148K increase.
  • Virtus Alternative Investment Advisers's biggest Q4 2020 reduction was Watsco Inc, cutting an estimated $101K.
  • Virtus Alternative Investment Advisers fully exited Merck in Q4 2020, selling an estimated $66K.
  • Virtus Alternative Investment Advisers's ten largest holdings make up 48% of its $6.71M portfolio in Q4 2020.
  • Virtus Alternative Investment Advisers opened 20 new positions and closed 6 in Q4 2020.
  • Virtus Alternative Investment Advisers's portfolio value rose 23% quarter-over-quarter to $6.71M.

Based on Virtus Alternative Investment Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.